Skip to content
Clinical Trials – home

Samodzielny Publiczny Zaklad Opieki Zdrowotnej W Lecznej

Verified siteinfo

Poland Ul. Krasnystawska 52, 21-010 Leczna, Poland

  • 8 trials recruiting
  • Colitis ulcerative · Crohn's disease · Acute respiratory failure
  • Adults and children

About Specializations

Samodzielny Publiczny Zaklad Opieki Zdrowotnej W Lecznej in Leczna, Poland specialises in clinical trials of conditions such as Colitis ulcerative, Crohn's disease, Acute respiratory failure, Coagulopathy, and other specialisations. This site conducts important research.

Main research areas of the site

Digestive System Diseases

The gastroenterology unit at Samodzielny Publiczny Zaklad Opieki Zdrowotnej W Lecznej is exploring new oral therapies aimed at reducing persistent symptoms in celiac disease patients who continue to experience discomfort despite a gluten‑free diet.

  • Assessment of novel capsule treatment for celiac disease
  • Patient‑reported outcome measurement using symptom diaries
  • Evaluation of mucosal healing in gluten‑sensitive individuals

Findings from these studies could lead to improved quality of life and better disease management for those affected.

Respiratory Tract Diseases

Researchers are examining the potential of an anti‑inflammatory antibody to protect patients with severe viral lung infection who require supplemental oxygen, aiming to lower the risk of death or progression to invasive ventilation.

  • Safety and efficacy of targeted antibody therapy in viral pneumonia
  • Impact on mortality and need for mechanical ventilation
  • Integration with standard of care for oxygen‑dependent patients

The work supports the hospital’s commitment to advancing treatments for acute respiratory illnesses.

Skin and Connective Tissue Diseases

A cutting‑edge study at the site evaluates a bilayer engineered collagen graft, denovoSkin™, for its ability to accelerate closure and reduce scarring in individuals with deep partial‑ and full‑thickness burns compared with traditional skin grafting.

  • Engineered skin substitute for severe burn injuries
  • Comparison with standard split‑thickness skin grafts
  • Assessment of wound healing speed and scar quality

Success could offer burn victims a faster recovery and improved cosmetic outcomes.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ul. Krasnystawska 5221-010 LecznaPoland
Recruiting now
8 trials
Conditions studied
9
Partner status
Verified site

More sites in LecznaPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

20 clinical trials

Crohn's disease

Recruiting

A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Crohn's disease

Recruiting

Study of RO7790121 (afimkibart) for Treatment and Long-term Management in Adults with Moderate to Severe Crohn's Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Study on Tozorakimab for Patients Hospitalized with Severe Viral Lung Infections Needing Oxygen

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tozorakimab
  • Sponsor:AstraZeneca AB

Coeliac disease

Recruiting

Study on ZED1227 for Improving Symptoms in Celiac Disease Patients on a Gluten-Free Diet

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Methyl (E,6S)-7-[[1-[2-(2-Ethylbutylamino)-2-Oxoethyl]-2-Oxopyridin-3-Yl]Amino]-6-[(3-Methylimidazole-4-Carbonyl)Amino]-7-Oxohept-2-Enoate
  • Sponsor:Dr. Falk Pharma GmbH

Phase 2 Randomized Double‑Blind Placebo‑Controlled Study of MH002 in Adults with Mild‑to‑Moderate Ulcerative Colitis Inadequately Controlled by 5‑ASA

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of Obefazimod for Patients with Moderate to Severe Crohn's Disease After Inadequate Response to Other Treatments

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Thermal burn

Recruiting

Study on the Effectiveness of EHSG-KF Skin Graft for Patients with Deep Partial and Full-Thickness Burns

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bilayer Engineered Collagen Hydrogel-Based Skin Graft Composed Of Autologous Keratinocytes And Fibroblasts
  • Sponsor:Cutiss AG

Crohn's disease

Recruiting

Study on Transmural Healing in Patients with Moderate to Severe Crohn's Disease Using Upadacitinib and Drug Combination

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Alimentiv Inc.

Coagulopathy

Not recruiting

Study on the Effectiveness of Human Coagulation Factor IX and Drug Combination for Patients with Major Bleeding on Factor Xa Inhibitor Therapy

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Protein C
  • Sponsor:Octapharma AG

Colitis ulcerative+1

Not recruiting

Study on the Long-Term Effects of TEV-48574 (Duvakitug) for Adults with Moderate to Severe Ulcerative Colitis or Crohn's Disease

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Teva Branded Pharmaceutical Products R&D LLC

Dyslipidaemia

Not recruiting

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Evolocumab
  • Sponsor:Amgen Inc.

Colitis ulcerative+1

Not recruiting

Study on the Effects of TEV-48574 for Adults with Moderate to Severe Ulcerative Colitis or Crohn's Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Teva Branded Pharmaceutical Products R&D LLC
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.